Symptoms, risk, screening and diagnostic confirmation

Detect Myeloma is about choosing the right test for the right risk.

A myeloma detection guide covering CRAB features, SPEP, immunofixation, serum free light chains, urine tests, bone marrow biopsy and whole-body imaging.

Screening reality Symptoms not to ignore Immunotherapy

Educational, not personal medical advice. Persistent bone/back pain, unexplained anemia, high calcium, kidney dysfunction, recurrent infections or abnormal total protein deserves targeted myeloma testing.

CRAB

calcium, renal, anemia and bone lesions.

SPEP

detects many monoclonal proteins.

Light chains

catch light-chain disease.

Imaging

low-dose whole-body CT/PET/MRI can reveal lytic lesions.

Brief outline

What myeloma means.

Multiple myeloma is a plasma-cell cancer. It can cause anemia, kidney injury, high calcium, bone pain, fractures and infections.

Myeloma bone marrow smear — Bone marrow confirms plasma-cell disease.

Detection frame

Screening is for people without symptoms. Diagnosis is for symptoms, abnormal examination, family history, imaging findings or abnormal labs. The same test can be sensible in one setting and misleading in another.

Do not ignore

Symptoms and signs not to ignore.

Bone or back painEspecially persistent, night pain or fractures.

Anemia fatigueOften the first lab clue.

Kidney dysfunctionLight chains can damage kidneys.

High calciumCan cause thirst, confusion, constipation and weakness.

InfectionsImmune suppression is common.

Neurologic symptomsSpinal cord compression is an emergency.

Risk and genetics

Demographics, risks and genetics.

AgeRisk rises with age.

MGUSA precursor state that needs risk-based follow-up.

Family historyFirst-degree relatives have higher risk.

RaceIncidence is higher in Black populations.

Radiation/occupational factorsAssociations exist but most cases are sporadic.

ObesityMay contribute risk.

Screening

Who should actually be screened?

There is no routine population screening program. MGUS or smoldering myeloma surveillance is different from screening the general public.

Blood

SPEP and immunofixation

Finds and types monoclonal protein.

Blood

Serum free light chains

Important for light-chain and non-secretory patterns.

Urine

UPEP/urine immunofixation

Can detect urinary light chains.

Confirm

Bone marrow biopsy

Measures plasma-cell burden and genetics.

Imaging

Whole-body low-dose CT/PET-CT/MRI

Assesses lytic lesions and focal marrow disease.

Caution

Borderline proteins

MGUS is common with age and not the same as myeloma.

Images, labs and tissue

Useful tests and what they can miss.

Detection usually needs a chain: suspicion, imaging or lab triage, tissue or cytology when needed, then pathology and molecular testing where it changes management.

PET-CT example — Whole-body imaging can reveal myeloma bone disease.

Full blood count example — Anemia is a common clue.

Pros, cons and controversy

Benefits, harms and the false-positive problem.

Earlier recognition prevents renal failure and fractures, but finding MGUS creates lifelong surveillance for many people who never develop myeloma.

Myeloma detection trials immunotherapyformyeloma.com DetectCancer.org hub

Sources and trials

Good starting points.

NCI plasma cell neoplasmsMyeloma overview and diagnosis. ClinicalTrials.gov myeloma detectionDiagnostic and surveillance trials.